Literature DB >> 14569211

Nephrogenic fibrosing dermopathy: the first 6 years.

Shawn E Cowper1.   

Abstract

PURPOSE OF REVIEW: Nephrogenic fibrosing dermopathy (NFD) is a newly recognized scleroderma-like fibrosing skin condition. It develops in patients with renal insufficiency. This review summarizes recent case reports and examines theories of disease pathogenesis. Information from the Yale University NFD Registry Project, as well as published case reports, is included to provide a contextual framework upon which to base these theories. RECENT
FINDINGS: Recent studies have contributed to a clearer definition of the clinical spectrum, epidemiology, and pathogenesis of NFD. The findings of yellow scleral plaques and circulating antiphospholipid antibodies have been proposed as markers of NFD in recent case reports. In addition, epidemiologic data have yielded several distinct clinical patterns of disease onset. Lastly, dual immunohistochemical staining for CD34 and procollagen in the spindle cells of NFD suggest that the dermal cells of NFD may represent circulating fibrocytes recruited to the dermis-a finding previously undescribed in normal skin.
SUMMARY: Scenario classification of NFD is a means for simplifying the search for multifactorial disease triggers, and may be helpful in predicting prognosis and response to therapy. The technique of dual immunolabeling, although not yet fully characterized as a diagnostic test, may provide a sensitive and specific method of diagnosis, as well as a starting point in the investigation of other cutaneous fibrosing disorders. The postulate that NFD may represent a systemic disorder mediated by aberrantly functioning circulating fibroblast precursor fibrocytes is explored.

Entities:  

Mesh:

Year:  2003        PMID: 14569211     DOI: 10.1097/00002281-200311000-00017

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  39 in total

Review 1.  Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.

Authors:  Caterina Ferreli; Giulia Gasparini; Aurora Parodi; Emanuele Cozzani; Franco Rongioletti; Laura Atzori
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

Review 2.  Nephrogenic systemic fibrosis: a concise review for cardiologists.

Authors:  Benjamin Y C Cheong; Raja Muthupillai
Journal:  Tex Heart Inst J       Date:  2010

Review 3.  Conventional or Gadolinium containing contrast media: the choice between acute renal failure or Nephrogenic Systemic Fibrosis?

Authors:  Alexander R Rosenkranz; Thomas Grobner; Gert J Mayer
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

4.  [Nephrogenic systemic fibrosis. Medical detective work in the 21st century].

Authors:  B Manger
Journal:  Z Rheumatol       Date:  2007-10       Impact factor: 1.372

5.  Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols.

Authors:  Diego R Martin; Saravanan K Krishnamoorthy; Bobby Kalb; Khalil N Salman; Puneet Sharma; John D Carew; Phillip A Martin; Arlene B Chapman; Gaye L Ray; Christian P Larsen; Thomas C Pearson
Journal:  J Magn Reson Imaging       Date:  2010-02       Impact factor: 4.813

6.  Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report.

Authors:  B J Edwards; A E Laumann; B Nardone; F H Miller; J Restaino; D W Raisch; J M McKoy; J A Hammel; K Bhatt; K Bauer; A T Samaras; M J Fisher; C Bull; E Saddleton; S M Belknap; H S Thomsen; E Kanal; S E Cowper; A K Abu Alfa; D P West
Journal:  Br J Radiol       Date:  2014-10       Impact factor: 3.039

7.  [Nephrogenic systemic fibrosis].

Authors:  W Samtleben
Journal:  Radiologe       Date:  2007-09       Impact factor: 0.635

8.  Nephrogenic systemic fibrosis: an unusual scleroderma-like fibrosing disorder.

Authors:  Eugenia Rota; Maria Gabriella Nallino; Serena Bainotti; Marco Formica
Journal:  Rheumatol Int       Date:  2009-08-20       Impact factor: 2.631

9.  Gadolinium-associated nephrogenic systemic fibrosis.

Authors:  June M McKoy; Anne Laumann; Athena Samaras; Mario Lacouture; Dennis West; Dennis Raisch; Eniola Obadina; Olukemi Fajolu; Lauren Reilly; Charles L Bennett
Journal:  Community Oncol       Date:  2008

10.  Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging.

Authors:  Constantina Chrysochou; Albert Power; Aladdin E Shurrab; Sayed Husain; Steven Moser; James Lay; Alan D Salama; Philip A Kalra
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-21       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.